Skip to main content

High-Concentration Capsaicin Patch Can Cut Neuropathic Pain Intensity

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 7, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 7, 2024 -- For patients with neuropathic pain, a high-concentration capsaicin patch (HCCP) is effective for reducing pain intensity, according to a study published online Feb. 7 in Pain Practice.

Kai-Uwe Kern, M.D., from the Institute of Pain Medicine/Pain Practice in Wiesbaden, Germany, and colleagues collected data from electronic medical records of patients who received at least two HCCP treatments between January 2011 and July 2022 to examine patient characteristics, concomitant analgesic medication, and pain intensity. The study included 97 patients, most of whom were diagnosed with neuropathic back pain, postoperative or posttraumatic neuropathic pain, and postherpetic neuralgia. The daily dose of concomitant medications was compared at the start of capsaicin therapy and within two years of capsaicin therapy.

The researchers found that most of the patients received concomitant medications, most often opioids, anticonvulsants, and antidepressants. During HCCP treatment, there was a significant decrease observed in the average daily morphine equivalent dose. At baseline, pain intensity was generally high, but patients who received at least three HCCP applications had substantial improvements.

"Our study shows that patients treated with at least two HCCP applications for different pain etiologies, such as neuropathic back pain or postoperative or post-traumatic neuropathic pain, seem to benefit from repeated HCCP applications," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Grünenthal GmbH, which funded the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted February 2024

Read this next

Degenerative Cervical Myelopathy Patients Often Have Severe Residual Paresthesia

MONDAY, March 11, 2024 -- Just under half of patients (45 percent) with degenerative cervical myelopathy (DCM) show severe residual paresthesia one year after surgery, according...

Pain Reduced With Target Muscle Reinnervation at Time of Amputation

WEDNESDAY, Jan. 10, 2024 -- For patients undergoing amputation, targeted muscle reinnervation (TMR) at the time of amputation improves pain scores and reduces the rate of neuroma...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.